| DC71013 |
BOC-L-Phenylalanine-13C |
BOC-L-Phenylalanine-13C is a 13C-labeled BOC-L-Phenylalanine. BOC-L-Phenylalanine is a derivative of Phenylalanine. |
|
| DC71052 |
Harmol |
Harmol categorized as a β-carboline alkaloid. Harmol is a potent MAO inhibitor used as an analytical reference standard. |
|
| DC71055 |
HZ52 |
HZ52 is a potent, reversible 5-lipoxygenase inhibitor, blocking leukotriene synthesis with an IC50 of 0.7 μM in intact human polymorphonuclear leukocytes. |
|
| DC71056 |
Imipramine N-oxide |
Imipramine N-oxide is the metabolite of Imipramine. Imipramine is a tertiary amine tricyclic antidepressant. |
|
| DC71075 |
Luffariellolide |
Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2) (IC50=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED50=50 μg/ear). |
|
| DC71086 |
Moveltipril |
Moveltipril is a potent angiotensin converting enzyme (ACE) inhibitor. |
|
| DC71092 |
NNGH
Featured
|
NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression. |
|
| DC71097 |
ONO-4817 |
ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit. |
|
| DC71116 |
Sonidegib metabolite M48 |
Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib. |
|
| DC71146 |
Nrf2-ARE/hMAO-B/QR2 modulator 1 |
Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC50s of 8.05, 9.83 and 0.57 μM for hMAO-B, NRF2 and QR2. Nrf2-ARE/hMAO-B/QR2 modulator 1 has neuroprotection, decreasing ROS production in okadaic acid-treated mice hippocampal slices. |
|
| DC71151 |
T-0156 |
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway. |
|
| DC71164 |
Vorozole |
Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer. |
|
| DC71171 |
Moexipril |
Moexipril is an orally active and potent angiotensin-converting enzyme (ACE) inhibitor. Moexipril can readily penetrate lipid membranes and thus target plasma and tissue ACE. Moexipril may improve endothelial dysfunction and exert neuroprotective effects. Moexipril can used for cardiovascular disease research. |
|
| DC71185 |
Protizinic acid |
Protizinic acid is an orally active non-steroidal antiinflammatory agent with antiinflammatory and antipyretic activity. Protizinic acid inhibits phospholipase A2 (PLA2) activity, and the IC50 value is 210 μM. |
|
| DC71190 |
6-trans-12-epi-Leukotriene B4 |
6-trans-12-epi-Leukotriene B4, an arachidonic acid metabolite, is a potent anti-inflammatory agent. |
|
| DC71191 |
9-PAHPA |
9-PAHPA is a fatty acid esters of hydroxy fatty acid (FAHFA). FAHFAs are a new family of endogenous lipids, have antidiabetic and anti-inflammatory effects. |
|
| DC71193 |
Ac-β-Ala-OH |
Ac-β-Ala-OH (N-Acetyl-β-alanine), an abnormal amino acid metabolite, is a mono-N-protected amino acid (MPAA) ligand. |
|
| DC71196 |
Guanidinoethyl sulfonate |
Guanidinoethyl sulfonate (Taurocyamine), a transport antagonist of taurine, induces much urinary taurine excretion with a resulting decrease in the tissue taurine content and readily produces taurine-deficient fetal rats in pregnant rats. Guanidinoethyl sulfonate, a structural analogue of taurine, acts as a competitive inhibitor of taurine transport. |
|
| DC71201 |
L-Kynurenine sulfate |
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype. |
|
| DC71210 |
l-α-tocopherol acetate-13C4,d6 |
l-α-tocopherol acetate-13C4,d6 is the 13C- and deuterium-labeled l-α-tocopherol acetate. l-α-tocopherol acetate is a natural tocopherol and has potent antioxidant activities. |
|
| DC71217 |
2-PAT |
2-PAT, an analogue of Rasagiline and Selegiline, a reversible MAO-A inhibitor with an IC50 of 0.721 µM. 2-PAT is an inactivator of MAO-B with an IC50 of 14.6 µM. 2-PAT has the potential for Parkinson’s disease and depression research. |
|
| DC71223 |
JG26 |
JG26 is an ADAM17 inhibitor, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM for ADAM8, ADAM17, ADAM10 and MMP-12, respectively. |
|
| DC71235 |
Cholestenone-13C |
Cholestenone-13C is the 13C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells. |
|
| DC71247 |
SAH-13C5 |
SAH-13C5 (SAH (S-Adenosylhomocysteine)-13C5) is the 13C-labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM. |
|
| DC71378 |
KS106 |
KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase. |
|
| DC71379 |
SYN20028567 |
SYN20028567 is an aromatase (CYP19) inhibitor with an IC50 of 9.4 nM. SYN20028567 can be used for breast cancer research. |
|
| DC71380 |
Clofenamide |
Clofenamide (Aquedux) is a carbonic anhydrase (CA) inhibitor. Clofenamide exhibits diuretic activity. |
|
| DC71381 |
Gü1303 |
Gü1303 is a potent, reversible, slow-binding cathepsin K (CatK) inhibitor with a Ki of 0.91 nM for mature CatK (mCatK). Gü1303 suppresses the autocatalytic activation of the cathepsin K zymogen. |
|
| DC71382 |
Gü2602 |
Gü2602 is a potent, reversible cathepsin K (CatK) inhibitor with a Ki of 0.013 nM for mature CatK (mCatK). Gü2602 suppresses the autocatalytic activation of the cathepsin K zymogen. |
|
| DC71383 |
ZC0101 |
ZC0101 is a potent, orally active IDO1 and TrxR dual inhibitor with IC50 values of 0.084 μM and 7.98 μM, respectively. ZC0101 effectively induces apoptosis and ROS accumulation in cancer cells. |
|
